SCPS (Scopus BioPharma) Quick Ratio: 0.05 (As of Jun. 2023)


What is Scopus BioPharma Quick Ratio?

Scopus BioPharma SCPS +50.00% Quick Ratio is 0.05 as of Jun. 2023.

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Scopus BioPharma's quick ratio for the quarter that ended in Jun. 2023 was 0.05.

Scopus BioPharma has a quick ratio of 0.05. It indicates that the company cannot currently fully pay back its current liabilities.

The historical rank and industry rank for Scopus BioPharma's Quick Ratio or its related term are showing as below:

SCPS's Quick Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 3.6
* Ranked among companies with meaningful Quick Ratio only.

Scopus BioPharma  (OTCPK:SCPS) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.

Scopus BioPharma Quick Ratio Related Terms

Scopus BioPharma Quick Ratio Historical Data

* Premium members only.

The historical data trend for Scopus BioPharma's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scopus BioPharma Quick Ratio Chart

Scopus BioPharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Quick Ratio
Get a 7-Day Free Trial 0.96 0.90 0.52 1.96 0.05

Scopus BioPharma Quarterly Data
Jun18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.31 0.07 0.05 0.17 0.05

SCPS vs AMPE, DRMA, SPRC: Quick Ratio Comparison

For the Biotechnology subindustry, Scopus BioPharma's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scopus BioPharma Quick Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scopus BioPharma's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Scopus BioPharma's Quick Ratio falls into.


Scopus BioPharma Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Scopus BioPharma's Quick Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Quick Ratio (A: Dec. 2022 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(0.39-0)/7.454
=0.05

Scopus BioPharma's Quick Ratio for the quarter that ended in Jun. 2023 is calculated as

Quick Ratio (Q: Jun. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(0.496-0)/11.002
=0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Quick Ratio →
What does a Quick Ratio of 0.05 mean?
Scopus BioPharma (SCPS) has a Quick Ratio of 0.05 as of Jun. 2023. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Scopus BioPharma and its competitors.
Is Scopus BioPharma's Quick Ratio too high?
Scopus BioPharma's current Quick Ratio is 0.05. The Biotechnology industry median Quick Ratio is 3.60. Scopus BioPharma's value of 0.05 is 98.6% below this industry median.
How does Scopus BioPharma's Quick Ratio compare to AMPE and DRMA?
Scopus BioPharma's Quick Ratio of 0.05 can be compared against companies in the Biotechnology industry. The industry median Quick Ratio is 3.60. Scopus BioPharma's value of 0.05 is 98.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Scopus BioPharma's current Quick Ratio of 0.05 is 98.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Scopus BioPharma and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scopus BioPharma's current Quick Ratio is 0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scopus BioPharma stock overvalued right now?
Scopus BioPharma (SCPS) has a current Quick Ratio of 0.05. The current Quick Ratio is 0.05 and 98.6% below the Biotechnology industry median of 3.60. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Scopus BioPharma (SCPS), the current Quick Ratio is 0.05 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scopus BioPharma Business Description

Address 420 Lexington Avenue, Suite 300, New York, NY, USA, 10170
Scopus BioPharma Inc a biotechnology company focused on developing therapeutics targeting the endocannabinoid system. The endocannabinoid system is comprised of chemical compounds, or cannabinoids, that interact with cannabinoid receptors which are located throughout the body. Its product candidate comprises CO-sTiRNA, which is a STAT3 inhibitor gene therapy and MRI-1867.